RECOVERY & TISSUE REPAIR RESEARCH / MATRIX
One Frame, Three Very Different Evidence Bases
GLOW, KPV, and TB-500 studied side by side on mechanism, tissue target, evidence depth, and the single caution that matters most for each.
The short version
This page lines up GLOW, KPV, and TB-500 on the dimensions that matter most when reading soft-tissue-repair peptide research: mechanism class, most-studied tissue, evidence depth (by species and sample size), administration route studied, regulatory/WADA status, and the single biggest caution for each. The honest summary: all three are studied for some form of tissue repair, but the evidence bases are not remotely comparable. TB-500's parent protein has the deepest and widest data set, including one human safety trial. KPV has five preclinical studies and zero human trials. GLOW has no trials of the blend at all — only trials of its three separate ingredients. None of the three is FDA-approved, and none of this is medical advice or a recommended dose.
The comparison matrix
| Dimension | GLOW (research blend) | KPV | TB-500 |
|---|---|---|---|
| Mechanism class | Multi-peptide combination: copper-tripeptide matrix signal (GHK-Cu) + pro-angiogenic gastric peptide (BPC-157) + actin-binding migration fragment (TB-500) | Melanocortin-derived anti-inflammatory tripeptide, PepT1-transported | Synthetic actin-binding heptapeptide fragment of thymosin beta-4 |
| Most-studied tissue | Skin/dermal matrix, wound and tendon recovery (via constituents) | Intestinal/gut mucosa (colitis models) | Tendon, skin, cornea, heart, and CNS (preclinical); wound re-epithelialization best characterized |
| Evidence depth | Zero blend trials; constituent data includes 3 small human BPC-157 pilots plus human GHK-Cu dermatology data [2][4] | 5 studies, all rodent/cell-line; 0 human trials [6][7][8][9][10] | Broad preclinical set (rat, mouse) plus 1 human Phase 1 IV safety trial, n=40, full-length protein [11][13][14][15][16] |
| Administration studied | Subcutaneous injection (community combination protocols; unstudied as a combination) | Oral / intraperitoneal in animal models only | Intraperitoneal / topical in animal models; intravenous in the one human trial (full-length protein) |
| Regulatory / WADA status | Not FDA-approved; contains 2 WADA-prohibited peptides (BPC-157, TB-500) [1] | Not FDA-approved; no specific WADA listing | Not FDA-approved; WADA-prohibited (peptide/growth-factor category) [1] |
| Key caution | Blend combines mismatched pharmacokinetics never characterized together | Zero human trials — efficacy and safety in people entirely unknown | Human data limited to the full-length protein; the marketed fragment has no dedicated human trial [12] |
Mechanism class
TB-500 and GLOW share a mechanism (TB-500 is one of GLOW's three components), so the real mechanistic split is two-versus-one: structural/vascular repair (GLOW, TB-500) versus inflammation control (KPV). Within the structural camp, GLOW adds two mechanisms TB-500 alone doesn't have — GHK-Cu's matrix-synthesis signal and BPC-157's angiogenic signal [3][4][5] — while TB-500 alone offers the single best-characterized mechanism of the three, actin sequestration, resolved to 2 angstroms by crystallography [14].
Most-studied tissue
KPV's literature is almost entirely about one organ: the inflamed gut, across DSS- and TNBS-induced colitis models [6][7][8][9]. TB-500's parent-protein literature is the broadest of the three, spanning dermal wounds [16], cardiac tissue after coronary ligation [15], and cerebral tissue after simulated stroke [11]. GLOW's tissue focus is nominally skin and connective tissue, inherited from its constituents rather than tested directly as a combination.
Evidence depth
By study count and species, KPV sits at 5 studies, all animal or cell-culture, zero human. TB-500's parent protein sits at roughly 6 core studies plus 1 completed human Phase 1 safety trial (n=40, IV, full-length protein) [13] — the single largest human data point among all three compounds and their constituents. GLOW has no blend-level studies; its 5 cited findings all describe one of its three ingredients tested alone, with BPC-157 additionally backed by three small human pilot studies [2].
Administration studied
All three are studied (or, for GLOW, its constituents are studied) as injections in their efficacy models — subcutaneous for community protocols, intraperitoneal or intravenous in controlled research. The only human route data point is intravenous, from TB-500's parent-protein Phase 1 trial [13]; no oral or subcutaneous human pharmacokinetic data exist for any of the three.
Regulatory and WADA status
None of the three has FDA approval for any indication. TB-500 is individually WADA-prohibited; because GLOW contains TB-500 (plus BPC-157, also prohibited), it inherits that same status, meaning a tested athlete cannot treat GLOW as a "skin" product exempt from anti-doping scrutiny [1]. KPV carries no specific WADA listing, though as an unapproved peptide it warrants the same caution.
Key caution
Each compound's defining caveat differs. For GLOW it is that the blend itself — three peptides with different clearance rates — has never been tested together, so every claim is an extrapolation from single-ingredient data. For KPV it is the complete absence of human trials: every number on this desk for KPV comes from a mouse, rat, or cell line. For TB-500 it is the fragment-versus-full-protein gap — most of the encouraging data describes a 43-residue protein, not the 7-residue piece sold under the name [12]. Read together, the pattern is consistent: preclinical promise is the norm across this frame, and human confirmation is the exception, not the rule.